Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POTOMAC: durvalumab + BCG versus BCG alone in high-risk BCG-naive non-muscle invasive bladder cancer
2017-002979-26Phase 3Unknown
- Sponsor
- AstraZeneca
- Start
- Feb 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-muscle-invasive bladder cancer (NMIBC) and bladder cancer comparing Durvalumab + BCG with BCG alone (2 arms). Primary endpoint: Disease-free survival. Status: unknown.
02
Drugs
durvalumabbcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)bladder cancer
Beyond the preview
Go deeper on 2017-002979-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002979-26.